1. INTRODUCTION {#sec1}
===============

1.1. Background {#sec1.1}
---------------

Infliximab (IFX) is a chimeric monoclonal IgG1 kappa antibody targeting tumor necrosis factor-alpha (TNFα) signaling inhibitor approved by Food and Drug Administration in US at 1998 \[[@r1]\], and is widely treated to immunological basis of inflammatory diseases such as rheumatoid arthritis (RA), \[[@r2]\] psoriatic arthritis (PsA) \[[@r3]\], Behcet syndrome (BD) \[[@r4]\], ankylosing spondylitis (AS) \[[@r5]\], plaque psoriasis (PPs) \[[@r6]\], inflammatory bowel disease (IBD) \[[@r7]\], Kawasaki disease (KD), \[[@r8]\] and Crohn disease (CD) \[[@r9]\]. The original IFX Remicade^TM^ has already expired its patent, and several biosimilar antibodies are available in the market \[[@r10]\]. Biological products such as therapeutic antibodies have a diverse category, and generally high-molecular-weight compounds \[[@r11]-[@r13]\]. Biosimilar is defined as a biological product that has highly similarity of character and no clinical and bioactive properties from an approved reference product \[[@r14]\]. However, the potential implications of the glycosylation profile changes in antibody production, especially in biosimilars, are one of the key factor for clinical efficacy and/or outcomes. And new technologies for multiple monitoring the glycosylation patterns have been recently reported using the selectivity and quantitation potentials of mass spectrometry \[[@r15]\]. There are currently two biosimilar products approved by FDA and EMA (CT-P13 from Celltrion/Hospira/Nihon-Kayaku and SB2 from Biogen/Merck). And in Japan, CT-P13 is only a biosimilar option. The original IFX and both biosimilar have been recently demonstrated to be fully interchangeable in regard to immunogenicity \[[@r16]\].

1.2. Significance of Infliximab Monitoring {#sec1.2}
------------------------------------------

Pharmacokinetic properties of IFX vary dependent on each disease. The half-life of IFX in circulation can be affected by combined immunosuppressive agents, and the concentration of TNFα and/or C-reactive protein (CRP). Moreover, some study showed that more than 23% of patients with CD met a secondary failure to IFX treatment for a year after IFX maintenance \[[@r17], [@r18]\]. Therefore, it should become significant that the therapeutic concentration management by IFX trough monitoring is improved with clinical response and prognosis \[[@r19]-[@r22]\]. And IFX treatment can be result in the formation of anti-infliximab antibodies (anti-drug antibodies, ADA). Filip *et al*. reported that ADA to IFX were detected in over 60% of patients in the treatment of CD, and ADA was associated with a decreased response to long-term efficacy \[[@r23]\]. The formation of ADA is certainly affected to immunogenicity, therefore a guide for clinical decision on next treatment strategy for secondary failure or partial response using anti-TNF biopharmaceuticals has been designed based on IFX and ADA monitoring \[[@r24]-[@r26]\]. These study strongly suggest that therapeutic drug monitoring (TDM) of IFX should support the therapeutic response to immunological basis of inflammatory diseases \[[@r27]-[@r29]\].

1.3. Current Technologies in Infliximab Monitoring {#sec1.3}
--------------------------------------------------

Currently, ligand-binding assay (LBA) is widely used to monitor IFX level, for example enzyme-linked immunosorbent assay (ELISA), digital ELISA, radioimmunoassay (RIA), and immunochromatography \[[@r30]\]. However, there are some remarkable issues in selectivity, linear dynamic range, cross reactivity, and the differences in quantitative data between various ELISA methods \[[@r31], [@r32]\]. Moreover, our data showed that coexistence of ADA was direct source of quantitative inhibition in ELISA assay, and the level of inhibition changed in dependence on the type of idiotypic antibody clones or its specific ligand \[[@r33]\]. Therefore, cross validation study should be necessary for IFX monitoring by LBA. To overcome these issues, clinical monitoring test such as TDM and pharmacokinetics should be carried out with the identical and practical assay method to exclude unexpected errors.

1.4. Development of LC-MS/MS based Global Therapeutic Antibody Monitoring {#sec1.4}
-------------------------------------------------------------------------

The feasibility of monitoring IFX and other therapeutic antibodies in human serum by liquid chromatography and tandem mass spectrometry (LC-MS/MS) has recently been advanced in several clinical laboratories \[[@r17], [@r34], [@r35]\]. Quantitation of tryptic signature peptide in antibodies can provide the high-sensitivity and selectivity, expectation for the prevention from IFX-specific binding substrates. Several approaches using LC-MS/MS have been reported such as fractionated pellet digestion, whole serum digestion, and hybrid LBA-LC-MS/MS, but these are limited applications \[[@r36]\]. In antibody bioanalysis by LC-MS/MS, there are several essential issues, such as separation ability in the LC, the ion suppression effect of the target molecule due to coexisting excess ions in the MS, maintenance of the ESI interface, and more than anything, universal use purpose for any antibodies. Recently, we have reported a sole LC-MS/MS bioanalysis method independent of a variety of antibodies \[[@r37]\]. The nSMOL (nano-surface and molecular-orientation limited proteolysis) chemistry is designed as a Fab-selective proteolysis of IgGs which maintaining antibody sequence specificity while minimizing additional analyte peptides and trypsin contamination. In this principle, trypsin immobilized on the surface of nanoparticle reacts by the physicochemically limiting trypsin access to the antibody substrate utilizing the diameter difference of immobilized trypsin particle and IgG collection resin pore. IgG molecules gather into the pore *via* Fc. Therefore, as a consequence, Fab is oriented to the reaction solution. We have already developed fully validated assays for multiplexed quantitation using nSMOL for many monoclonal antibodies \[[@r38]-[@r42]\]. These results show the significant value of regulated LC-MS analysis. In this report, we have discussed the validated analysis of IFX in human serum for TDM application and its biosimilar reciprocal verification using the same condition of IFX assay.

2. MATERIALS AND METHOD {#sec2}
=======================

2.1. Chemicals {#sec2.1}
--------------

nSMOL^TM^ Antibody BA kit for monoclonal antibody quantitation and reaction socket tubes was commercially available from SHIMADZU Corporation (Kyoto, Japan). Infliximab original Remicade^TM^ was obtained from Mitsubishi Tanabe Pharma (Osaka, Japan), and biosimilar Infliximab NK^TM^ (CT-P13) was from Nippon-Kayaku (Tokyo, Japan). Individual three male and female human serums was from Kohjin Bio (Saitama, Japan). P14R, a synthetic peptide for internal standard was from Sigma Aldrich (St. Louis, MO). Ultrafree-MC GV centrifugal 0.22 μm filter was from Merck Millipore (Billerica, MA). Other reagents, buffers, and solvents were purchased from Sigma-Aldrich and Wako Pure Chemical Industries (Osaka, Japan).

2.2. Signature Peptide Identification of IFX {#sec2.2}
--------------------------------------------

Signature peptide identification of IFX was carried out according to our previous studies. We aligned the amino acid sequences by ClustalW analysis using four chimeric antibody sequences for Infiximab (Kyoto Encyclopedia of Genes and Genomes KEGG Drug entry D02598), Rituximab (RTX, D02994), Brentuximab vedotin (BRX, D09587), and Cetuximab (CTX, D03455) in [Fig. (**[1](#F1){ref-type="fig"}**)](#F1){ref-type="fig"}. The tryptic peptide identification was achieved by high-resolution LCMS-IT-TOF MS (SHIMADZU, Kyoto, Japan) and Mascot (Matrix Sciences, London, UK) in-house proteome database server. And these identified data were confirmed and organized by the information-based software Skyline (MacCoss, University of Washington) \[[@r43]\]. The LCMS conditions were as follows: solvent A, 0.1% aqueous formic acid; solvent B, acetonitrile with 0.1% formic acid; column, L-column2 ODS, 2.1x150 mm, 2 μm, 10 nm pore (Chemicals Evaluation and Research Institute, Tokyo, Japan); column temperature, 40°C; flow rate, 0.2 ml/min; gradient program, 0-5 min: %B=3, 5-35 min: %B=3-30 gradient, 35-46 min: %B=95, 46-55 min: %B=3. MS and MS/MS spectra were obtained with the desolvation line and heat block temperature at 200°C, respectively. Nebulizer nitrogen gas flows were set to 1.5 liter/min. Drying gas pressure was 100 kPa. Ion accumulation time was 30 msec for MS, and 70 msec for MS/MS analysis. MS/MS analysis was performed by automated data dependent mode. Ar pulse time into ion trap cell was 125 μsec. The electrode of collision-induced dissociation (CID) cell was set at -1.5 V. Using the identified peptide structure, predicted CDR (complementarity-determining region)-containing peptides were selected as candidate signature peptides after comparison with ClustalW results.

2.3. Signature Peptide Selection of IFX in Human Serum {#sec2.3}
------------------------------------------------------

The selected candidate signature peptides were verified by the addition of each antibody in serum and the preparation of a set of diluted samples. nSMOL reaction proceeded as follows: All control and test samples were filtered by 5 μm and then by 0.65 μm filter devices to remove debris. And all protocols were followed by nSMOL kit protocols with minor modification. Briefly, a 5 μL aliquot of antibody-spiked human serum was diluted 10-fold in washing solution 1. The IgG fraction in serum was collected in 12.5 μL of immunoglobulin collection resin with gentle vortexing at 25°C for 5 min. Nonspecific binding to resin was washed twice with 300 μL of washing solution 1 and then with 300 μL of washing solution 2. And washed resin was suspended in 75 μL of enhanced reaction solution containing 10 fmol/μL P14R peptide. nSMOL proteolysis was accomplished by 10 μL FG-beads on trypsin with gentle vortexing at 50°C for 5 h under saturated vapor atmosphere. nSMOL reaction was quenched by addition of quenching solution. The peptide solution was collected by centrifugation (10,000 g for 1 min) and magnetic separation to remove collection resin and FG-beads. These analytes were transferred into low protein binding polypropylene vials, and then analyzed by triple quadrupole LCMS-8050 (SHIMADZU). The LC-MS conditions were as follows: solvent A, 0.1% aqueous formic acid; solvent B, acetonitrile with 0.1% formic acid; column, Shim-pack GISS C18, 2.1x50 mm, 1.9 μm, 20 nm pore (SHIMADZU); column temperature, 50°C; flow rate, 0.4 ml/min; gradient program, 0-1.5 min: %B=5, 1.5-4 min: %B=5-45 gradient, 4-4.8 min: %B=95 with flow rate 1 ml/min, 4.8-5.2 min: %B=1 with flow rate 1 mi/min, and 5.2-6 min: %B=5. MS spectra were obtained with the ESI probe temperature, desolvation line and heat block at 300°C, 250°C and 400°C, respectively. Nebulizer, heating, and drying nitrogen gas flows were set to 3, 10, and 10 liters/min, respectively. The dwell time was set to 10 msec for each transition. MRM (multiple reaction monitoring) monitor ions of peptide fragments were imported from the measured values of structure-assigned fragments by high-resolution LC-MS analysis. CID gas of argon partial pressure in Q2 cell was set to 270 kPa. The electrode voltage of Q1 pre bias, collision cell Q2, Q3 pre bias, parent and fragment ion m/z were performed by optimization support software (LabSolutions, Shimadzu). Peptide structure-indicated MRM signals with good correlation to drug concentration were selected as the signature peptide transitions of each antibody drugs. Finally, for the setting of MRM transition, we selected the most marked b- or y-ion series fragment as a quantitation, and additional fragment as a structure confirmation. In Infliximab assay, peptides SINSATHYAESVK (aa.55-67 on H-chain), YASESMSGIPSR (aa.50-61 on L-chain), and ASQFVGSSIHWYQQR (aa.25-39 on L-chain) were selected as signature peptides for Infliximab quantitation. Each MRM chromatogram of three signature peptides is shown in supplementary materials (Fig. **S1-S3**).

2.4. Method Verification between Original and Biosimilar IFX {#sec2.4}
------------------------------------------------------------

The analytical method was first validated in accordance with the Guideline on Bioanalytical Method Validation in Pharmaceutical Development from Notification 0711-1 of the Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, the Ministry of Health, Labour and Welfare, dated July 11, 2013. The summary of validation data was shown in [Tables 1](#T1){ref-type="table"} to [7](#T7){ref-type="table"}. All validation sample set were prepared and stored at -80°C for 24 h or more before each validation assay. The concentrations of IFX in human serum were set from 0.293 to 300 μg/ml with 2-fold serial dilution as 11 calibration samples. The concentrations of lower limit of quantification (LLOQ), low quality control (LQC), middle quality control (MQC) and high quality control (HQC) were set 0.293, 0.879, 14.1 and 240 μg/ml, respectively.

3. RESULTS {#sec3}
==========

3.1. Selection of IFX Signature Peptides for Practical Clinical Bioanalysis {#sec3.1}
---------------------------------------------------------------------------

Selected signature peptides of IFX bioanalysis are shown by ClustalW alignment in [Fig. (**[1](#F1){ref-type="fig"}**)](#F1){ref-type="fig"}. We have several criteria for the selection of good signature peptide: peptides with about 8 to 15 amino acid sequences, with no missed cleavage of trypsin, exclusion of close to the position of conserved disulfide bonding on the framework. Five candidate peptides were detected and identified from CDR-containing domain on Fv region. [Fig. (**[2](#F2){ref-type="fig"}**)](#F2){ref-type="fig"} shows the 3D configuration on antibody structure, so that nSMOL reaction was very successfully reacted on high Fv-selective manner similar to our previous reports like Trastuzumab, Bevacizumab, and

Nivolumab, etc. To best our knowledge, nSMOL technology is a novel and broad approach for the Fv-selective bioanalysis of therapeutic monoclonal antibodies. And in Table **[1](#T1){ref-type="table"}**, MRM conditions for candidate signature peptides of IFX and P14R synthetic internal standard are summarized by using LCMS-8050/8060 (SHIMADZU). We recommend that MRM transitions of quantitation and structure confirmation should be acquired at the same time because of the selectivity verification by its structure indexes from several biological matrices.

3.2. nSMOL Assay Validation Using Signature Peptide SINSATHYAESVK {#sec3.2}
-----------------------------------------------------------------

The assay was validated in accordance with the Guideline on Bioanalytical Method Validation in Pharmaceutical Development from Notification 0711-1 of the Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, the Ministry of Health, Labour and Welfare, dated July 11, 2013 for low-molecular-weight drug compounds. And for the other two peptides YASESMSGIPSR and ASQFVGSSIHWYQQR validation data, we have summarized in supplementary materials (Table **S1**-**S6**).

### 3.2.1. Linearity and Calibration Standard {#sec3.2.1}

The linearity of nSMOL bioanalysis (Table **[2](#T2){ref-type="table"}**) was evaluated by the analysis of 11 calibration standards (zero sample, 0.293, 0.586, 1.17, 2.34, 4.69, 9.38, 18.8, 37.5, 75.0, 150, and 300 µg/ml) using linear regression model including the pharmacokinetic study of IFX. The calibration plot was used the 1/Area2 weighting. The accuracy at LLOQ was 96.7-103%, and other concentration set were 90.1-113%. And using the same condition of Remicade, NK calibration set provided almost the same results (Table **[3](#T3){ref-type="table"}**). These data suggest that original and biosimilar product have a very similar conformation and equal nSMOL reaction efficiency.

### 3.2.2. Carryover Test {#sec3.2.2}

The carryover test was performed by analyzing 3 replicates for IFX peptide from Remicade and NK just after the analysis of maximum concentration set (300 µg/ml). The carryover was calculated as the response cps value in the blank serum compared with the LLOQ sample. In nSMOL analysis, low level of carryover was observed for the IFX peptide being about 10%, having no influence on this analysis (Table **[4](#T4){ref-type="table"}**).

### 3.2.3. Precision and Accuracy in Inter- and intra-assay {#sec3.2.3}

Precision and accuracy data were confirmed by the analysis of human serum validation sample at LLOQ, LQC, MQC, and HQC concentration of Remicade (Table **[5](#T5){ref-type="table"}**) and NK (Table **[6](#T6){ref-type="table"}**). The intra-day and inter-day precision and accuracy were determined by analyzing 5 QC sample sets at 4 concentrations on 3 different days. These data were summarized in Table **[5](#T5){ref-type="table"}** for Remicade: precision and accuracy of run 1, 98.9% and 7.53% at LLOQ, 99.5-111% and 1.56-6.60% at other set; run 2, 94.8% and 11.7% at LLOQ, 97.5-104% and 2.02-6.78% for other; run 3, 111% and 5.65% for LLOQ, 97.7-106% and 0.78-10.2% for other; 102% and 10.4% for LLOQ, 98.2-105% and 2.19-8.83% for other set of intra-assay (N=15) results. And same as in NK assay results were shown in Table **[6](#T6){ref-type="table"}**.

### 3.2.4. Processed Sample Stability {#sec3.2.4}

The processed sample stability after nSMOL reaction at 5°C for 24 and 48 hours were demonstrated at the concentration of LQC and HQC. Accuracy of LLOQ and HQC were 101-103% and 93.3-95.3, respectively (Table **[7](#T7){ref-type="table"}**).

### 3.2.5. Cross Verification between Original and Biosimilar IFX {#sec3.2.5}

In order to apply a broad TDM application for many inflammatory immune diseases by nSMOL bioanalysis, cross verification assay of Remicade quantitation by NK standard set, and its opposite combination, was carried out and summarized in Tables **[8](#T8){ref-type="table"}** and **[9](#T9){ref-type="table"}**. In these two combination, precision and accuracy at LLOQ were 104% and 92.9%, 7.54% and 8.27%; 91.8-102%, 1.48-9.11% at other concentration set, respectively.

4. DiscussIon {#sec4}
=============

nSMOL chemistry is Fab-selective proteolysis with maintaining antibody sequence specificity while minimizing a large excess of tryptic peptide analyte. Therefore, the analytical validation condition can be easily set in a short time. In LC-MS/MS based bioanalysis, excess analyte injection causes the severe ionization suppression effect. This issue has been essential for the development of regulated LC-MS bioanalysis for the practical clinical application. In this study, we have developed the validated IFX and its biosimilar analysis in human serum within the guideline criteria for pharmaceutical development, and this method is expected to be applied to many therapeutic antibody monitoring for inflammatory immune diseases. In RISING study of RA, trough concentration of IFX level at week 54 showed the good references for clinical responses, and higher serum level of IFX above 1 μg/ml provided more effective responses and prognosis \[[@r44]\]. The nSMOL validation data indicate that our new assay can be enough analyzed at this reference levels.

The recent NOR-SWITCH trial switching from original IFX to biosimilar showed that CT-P13 was similar in safety and immunogenicity to the continued treatment for the CD, RA, ulcerative colitis, and several inflammatory immune diseases, and that switching to biosimilar is allowable \[[@r45]\]. However, the author also recommended that these results cannot be generalized to other biosimilar antibodies because of the possibility for too wide clinically differences of 15% margin. Same as this significant switching study, we propose that the data of comparative clinical assays or bioanalysis can be performed on the identical platform by demonstrating the cross validation between original and biosimilar antibodies. nSMOL assay coupled with LC-MS/MS can be provided the bioanalysis data for monoclonal antibodies with less errors within 15% because this technology is based on biochemical and physicochemical proof \[[@r46]\].

Recently, several reports showed that IFX treatment is advocated for the management of immune-related adverse events (irAEs) like enterocolitis or pneumonitis induced by the immune checkpoint inhibitors \[[@r47], [@r48]\]. In the case of irAE management using IFX, serum or plasma concentration of IFX may be related to the inflammatory observation. Moreover, IFX monitoring should be carried out in coexistence with other anti-immune checkpoint antibodies, and be strictly separated from the interference of other antibodies. The nSMOL have already been succeeded the multiplex antibody bioanalysis, and we suggest that this approach have a potential to apply to this clinical trials or drug-drug interaction assay.

Conclusion
==========

In conclusion, we have developed the validated LC-MS/MS based IFX monitoring in circulation using our nSMOL technologies. This approach will be expected to develop an optimal administration strategy in RA or other inflammatory immune diseases. And this approach will be adjusted for many monoclonal antibody or biosimilar analysis and rapid application for new clinical trials.
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![ClustalW sequence alignment of Infliximab (IFX), Rituximab (RTX), Brentuximab vedotin (BRX), and Cetuximab (CTX) of **a**)  H-chain alignment and **b**) L-chain alignment. Black area is shown as a framework structure with common amino acid sequences. And, Gray is similar amino acid position. White and blank are shown the different and deletion amino acid position. Red line squares show the candidate signature peptide for IFX quantitation by nSMOL bioanalysis.](CPB-19-495_F1){#F1}

![Signature peptide configuration of IFX into 3D antibody structure. Green color shows the signature peptides from IFX H-chain, and red is from L-chain. nSMOL successfully reacted as Fv-selective manner.](CPB-19-495_F2){#F2}

###### 

MRM transition summary for Infliximab signature peptide candidate.

  ---------------------------------------------------------------------------------------------------------------
  **Selected Peptide**   **Region**          **Optimal MRM Condition**   **Role**                 
  ---------------------- ------------------- --------------------------- ---------- ------ ------ ---------------
  SINSATHYAESVK          H-chain of CDR2     469.8\>603.9 (y11 ^++^)\    -46\       -16\   -34\   Quantitation\
                                             469.7\>547.0 (y10 ^++^)     -46        -17    -28    Structure

  GLEWVAEIR              H-chain of CDR2     536.8\>773.4 (y6 ^+^)\      -45\       -19\   -34\   Quantitation\
                                             536.8\>488.4 (y4 ^+^)       -45        -18    -24    Structure

  SAVYLQMTDLR            H-chain of CDR3     649.0\>876.4 (y8 ^+^)\      -40\       -24\   -32\   Quantitation\
                                             649.0\>763.3 (y6 ^+^)       -40        -23    -40    Structure

  ASQFVGSSIHWYQQR        L-chain of CDR1     598.8\>631.5 (y10 ^++^)\    -44\       -17\   -32\   Quantitation\
                                             598.8\>754.5 (y12 ^++^)     -44        -21    -30    Structure

  YASESMSGIPSR           L-chain of CDR2     642.8\>834.4 (y8 ^+^)\      -40\       -25\   -30\   Quantitation\
                                             642.9\>359.4 (y3 ^+^)       -40        -22    -10    Structure

  P14R                   Internal standard   512.1\>292.3 (b3 ^+^)\      -40\       -20\   -20\   Quantitation\
                                             512.1\>389.3 (b4 ^+^)       -40        -16    -28    Structure
  ---------------------------------------------------------------------------------------------------------------

###### 

Calibration curve reproducibility of SINSATHYAESVK H-chain peptide from Remicade.

  **Set Conc. \[µg/ml\]**   **Back-calculated Conc. \[µg/ml\]**   **Accuracy (%)**                         
  ------------------------- ------------------------------------- ------------------ ------- ------ ------ ------
  0.293                     0.283                                 0.286              0.302   96.7   97.7   103
  0.586                     0.609                                 0.606              0.528   104    103    90.1
  1.17                      1.21                                  1.19               1.32    104    102    113
  2.34                      2.31                                  2.26               2.41    98.5   96.6   103
  4.69                      4.78                                  4.87               4.88    102    104    104
  9.38                      9.82                                  8.93               9.83    105    95.2   105
  18.8                      18.4                                  19.0               19.2    98.1   101    102
  37.5                      37.4                                  38.6               37.7    99.7   103    100
  75.0                      74.9                                  79.0               72.3    99.8   105    96.4
  150                       156                                   145                145     104    96.9   96.8
  300                       276                                   293                280     92.0   97.6   93.5

###### 

Calibration curve reproducibility of SINSATHYAESVK H-chain peptide from NK.

  **Set Conc. \[µg/ml\]**   **Back-calculated Conc. \[µg/ml\]**   **Accuracy (%)**                         
  ------------------------- ------------------------------------- ------------------ ------- ------ ------ ------
  0.293                     0.287                                 0.278              0.284   98.1   94.9   96.9
  0.586                     0.657                                 0.673              0.581   112    115    99.1
  1.17                      1.02                                  1.16               1.27    87.6   98.8   105
  2.34                      2.42                                  2.19               2.51    103    93.7   107
  4.69                      4.96                                  5.03               4.74    106    107    101
  9.38                      9.89                                  8.80               10.2    105    93.8   109
  18.8                      19.6                                  20.1               18.3    104    107    97.2
  37.5                      36.7                                  38.5               38.0    97.7   103    106
  75.0                      71.9                                  70.6               69.7    95.9   94.2   92.9
  150                       146                                   152                143     97.1   101    95.4
  300                       302                                   300                298     101    100    99.4

###### 

Carryover test of SINSATHYAESVK.

  **Compounds**   **Run**   **Pear Area cps**   **Area%**           
  --------------- --------- ------------------- ----------- ------- ------
  Remicade        1         9,626               5,601,867   709     7.37
  2               9,366     5,201,490           887         9.47    
  3               8,487     5,363,308           849         10.0    
  NK              1         8,321               5,987,371   1,151   13.8
  2               8,128     5,734,701           661         8.13    
  3               8,113     5,533,250           606         7.47    

###### 

Precision and accuracy data of SINSATHYAESVK from Remicade.

  **Run**   **Set Conc.**   **Concentration \[µg/ml\]**                  
  --------- --------------- ----------------------------- ------- ------ -----
  1         Observed        0.275                         0.915   14.9   245
  0.303     1.04            14.7                          238            
  0.290     0.898           15.2                          238            
  0.318     0.974           14.9                          234            
  0.263     1.03            14.0                          239            
  Mean      0.290           0.971                         14.7    239    
  SD        0.02            0.06                          0.45    3.72   
  CV (%)    7.53            6.60                          3.06    1.56   
  ACC (%)   98.9            111                           105     99.5   
  2         Observed        0.254                         0.954   14.6   247
  0.295     0.846           15.0                          230            
  0.253     0.812           14.5                          238            
  0.327     0.926           14.9                          225            
  0.260     0.851           14.3                          231            
  Mean      0.278           0.878                         14.6    234    
  SD        0.03            0.06                          0.30    8.49   
  CV (%)    11.7            6.78                          2.02    3.63   
  ACC (%)   94.8            99.9                          104     97.5   
  3         Observed        0.310                         0.792   14.8   234
  0.337     0.886           15.0                          237            
  0.301     0.986           15.1                          232            
  0.334     0.793           15.0                          234            
  0.343     0.955           14.7                          236            
  Mean      0.325           0.882                         14.9    235    
  SD        0.02            0.09                          0.18    1.84   
  CV (%)    5.65            10.2                          1.18    0.78   
  ACC (%)   111             100                           106     97.7   
  N=15      Mean            0.298                         0.910   14.8   236
  SD        0.03            0.08                          0.32    5.51   
  CV (%)    10.4            8.83                          2.19    2.34   
  ACC (%)   102             104                           105     98.2   

###### 

Precision and accuracy data of SINSATHYAESVK from NK.

  **Run**     **Set Conc.**   **Concentration \[µg/ml\]**                    
  ----------- --------------- ----------------------------- --------- ------ -----
  1           Observed        0.278                         0.822     14.6   213
  0.217       0.824           14.8                          220              
  0.279       0.779           14.4                          211              
  0.273       0.877           14.5                          232              
  **Run**     **Set Conc.**   **Concentration \[µg/ml\]**                    
  **0.293**   **0.879**       **14.1**                      **240**          
                              0.271                         0.800     14.2   228
  Mean        0.264           0.820                         14.5      221    
  SD          0.03            0.04                          0.22      8.99   
  CV (%)      9.96            4.46                          1.52      4.07   
  ACC (%)     90.0            93.3                          103       92.0   
  2           Observed        0.240                         0.885     14.1   245
  0.264       0.895           14.4                          223              
  0.293       0.887           14.1                          227              
  0.241       0.874           13.9                          238              
  0.253       0.870           14.3                          230              
  Mean        0.258           0.882                         14.2      233    
  SD          0.02            0.01                          0.17      8.62   
  CV (%)      8.44            1.15                          1.17      3.70   
  ACC (%)     88.1            100                           100       97.0   
  3           Observed        0.317                         0.899     13.8   230
  0.285       0.967           14.8                          227              
  0.315       0.948           14.7                          226              
  0.303       0.866           15.0                          227              
  0.312       0.878           14.9                          234              
  Mean        0.306           0.912                         14.6      229    
  SD          0.01            0.04                          0.49      3.35   
  CV (%)      4.28            4.83                          3.38      1.47   
  ACC (%)     105             103.7                         104       95.3   
  N=15        Mean            0.276                         0.871     14.4   227
  SD          0.03            0.05                          0.37      8.61   
  CV (%)      10.8            5.75                          2.54      3.79   
  ACC (%)     94.2            99.1                          102       94.8   

###### 

Processed sample stability of quantitation data using signature peptide SINSATHYAESVK.

  **Time**   **Store at 5°C**   **Concentration \[µg/ml\]**                 
  ---------- ------------------ ----------------------------- ----- ------- -----
  24 hours   Mean               0.893                         224   0.886   224
  ACC%       102                93.3                          101   93.3    
  48 hours   Mean               0.888                         229   0.908   225
  ACC%       101                95.3                          103   93.6    

###### 

nSMOL assay verification of biosimilar NK using original Remicade standard.

  **Compounds**     **Set Conc.**   **Concentration \[µg/ml\]**                  
  ----------------- --------------- ----------------------------- ------- ------ -----
  NK quantitation   Observed        0.318                         0.806   14.3   229
  0.291             0.970           14.7                          229            
  0.333             0.765           13.6                          248            
  0.306             0.855           14.5                          234            
  0.274             0.878           14.6                          240            
  Mean              0.304           0.855                         14.4    236    
  SD                0.02            0.08                          0.45    8.05   
  CV (%)            7.54            9.11                          3.16    3.41   
  ACC (%)           104             97.2                          102     98.4   

###### 

nSMOL assay verification of original Remicade using biosimilar NK standard.

  **Compounds**     **Set Conc.**   **Concentration \[µg/ml\]**                  
  ----------------- --------------- ----------------------------- ------- ------ -----
  NK quantitation   Observed        0.295                         0.957   14.2   217
  0.259             0.839           13.7                          231            
  0.244             0.883           13.8                          212            
  0.268             0.891           14.0                          212            
  0.295             0.827           13.8                          230            
  Mean              0.272           0.879                         13.9    220    
  SD                0.02            0.05                          0.21    9.53   
  CV (%)            8.27            5.84                          1.48    4.32   
  ACC (%)           92.9            100                           98.6    91.8   
